These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 10648390)

  • 1. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
    Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
    Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients.
    Liu D; Tammik C; Zou JZ; Ernberg I; Masucci MG; Ringden O; Levitsky V
    Clin Transplant; 2004 Oct; 18(5):518-24. PubMed ID: 15344953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
    Lucas KG; Small TN; Heller G; Dupont B; O'Reilly RJ
    Blood; 1996 Mar; 87(6):2594-603. PubMed ID: 8630428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
    Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
    Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.
    Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ
    Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
    Rooney CM; Smith CA; Ng CY; Loftin SK; Sixbey JW; Gan Y; Srivastava DK; Bowman LC; Krance RA; Brenner MK; Heslop HE
    Blood; 1998 Sep; 92(5):1549-55. PubMed ID: 9716582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
    Marshall NA; Howe JG; Formica R; Krause D; Wagner JE; Berliner N; Crouch J; Pilip I; Cooper D; Blazar BR; Seropian S; Pamer EG
    Blood; 2000 Oct; 96(8):2814-21. PubMed ID: 11023516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
    Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
    Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
    Doubrovina E; Oflaz-Sozmen B; Prockop SE; Kernan NA; Abramson S; Teruya-Feldstein J; Hedvat C; Chou JF; Heller G; Barker JN; Boulad F; Castro-Malaspina H; George D; Jakubowski A; Koehne G; Papadopoulos EB; Scaradavou A; Small TN; Khalaf R; Young JW; O'Reilly RJ
    Blood; 2012 Mar; 119(11):2644-56. PubMed ID: 22138512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-specific cytotoxic T lymphocytes as prophylaxis for Epstein-Barr virus lymphoproliferative disease in pediatric bone marrow transplant recipients.
    Norville R; Nance D; Cheshire S
    J Pediatr Oncol Nurs; 1997 Oct; 14(4):194-201. PubMed ID: 9322393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
    Smith CA; Ng CY; Heslop HE; Holladay MS; Richardson S; Turner EV; Loftin SK; Li C; Brenner MK; Rooney CM
    J Hematother; 1995 Apr; 4(2):73-9. PubMed ID: 7633844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
    Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
    Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation.
    Yoshimi A; Tsuge I; Namizaki H; Hoshino Y; Kimura H; Takahashi Y; Watanabe N; Kuzushima K; Kojima S
    Br J Haematol; 2002 Mar; 116(3):710-5. PubMed ID: 11849237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
    Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
    Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
    Rooney CM; Smith CA; Ng CY; Loftin S; Li C; Krance RA; Brenner MK; Heslop HE
    Lancet; 1995 Jan; 345(8941):9-13. PubMed ID: 7799740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
    Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
    Leen AM; Christin A; Myers GD; Liu H; Cruz CR; Hanley PJ; Kennedy-Nasser AA; Leung KS; Gee AP; Krance RA; Brenner MK; Heslop HE; Rooney CM; Bollard CM
    Blood; 2009 Nov; 114(19):4283-92. PubMed ID: 19700662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBV specific CTL: a model for immune therapy.
    Rooney CM; Heslop HE; Brenner MK
    Vox Sang; 1998; 74 Suppl 2():497-8. PubMed ID: 9704488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.